News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Osteoporosis Medicine Decision Welcomed

Media Release

Tuesday 27 September 2005

Osteoporosis Medicine Decision Welcomed

The decision to widen taxpayer-funded access to the osteoporosis medication Fosamax® will result in significant quality of life improvements for the estimated 30% of New Zealand women over the age of 50 who have osteoporosis.

“Fosamax is the only medicine available for osteoporosis conclusively proven1,2 in clinical trials to reduce the risk of fractures at all the key osteoporosis sites – the hip, spine and wrist,” said Alister Brown, managing director of Merck Sharp & Dohme – which developed Fosamax and markets the prescription medicine in New Zealand.

“Having wider taxpayer-funded access to Fosamax has been long awaited by patients and the medical community, who I am sure will applaud this decision.”

Fosamax was approved for use in postmenopausal osteoporosis by the NZ regulatory agency MEDSAFE in September 1995. An application for subsidised access to Fosamax for patients with osteoporosis was made that same year. In February 2000, PHARMAC provided taxpayer-funded access to Fosamax for patients with two prior osteoporotic fractures and very low bone mass (three standard deviations below the mean normal value in young adults: a ‘T-Score’ of 3.0).

From 1 October 2005, wider access criteria for Fosamax will include patients with either one previous osteoporotic fracture and a bone mineral density T-Score of 2.5 or more; or a history of two significant osteoporotic fractures; or a T-Score of 3.0 or above; or one osteoporotic fracture and either the patient is elderly or densitometry scanning cannot be performed for one of a number of reasons.

“It’s good news for patients and the health sector that PHARMAC and Merck Sharp & Dohme have been able to work together to reach this agreement,“ Alister Brown said.

“Osteoporosis is a serious illness which reduces the quality of life of many New Zealanders. However, this agreement will not only improve quality of life for a large number of women with osteoporosis and a small number of men with the condition. By preventing fractures, this deal will also reduce public and private sector expenditure on fracture treatment across the health sector.”

Note: The clinical name for Fosamax is alendronate. It is packaged, sold and known to patients and the general public in New Zealand as Fosamax.


Therapeutic Advertising Pre-Vetting System (TAPS) no. NZ9837

® Registered trademark of Merck & Co. Inc, Whitehouse Station, NJ, USA. PRESCRIPTION MEDICINE

1. Bone et al, New England Journal of Medicine, 2004, Vol. 350, 1189-99
2. Black et al, Journal Of Clinical Endocrinology & Metabolism: 2000, Vol. 85, No. 11, 4118-4124

THINGS TO KNOW BEFORE USING FOSAMAX (alendronate) 10 & 70 mg tablets:
FOSAMAX is indicated for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). FOSAMAX should not be taken by patients who have a hypersensitivity reaction, food pipe (oesophageal) abnormalities, low calcium (hypocalcaemia) and have an inability to stand/sit upright for 30mins. Precaution should be taken when administering FOSAMAX to patients with active upper gastrointestinal problems, impaired renal function and calcium or vitamin D deficiency. Common side effects are: abdominal pain, dyspepsia, food pipe (oesophageal) ulcer, difficulty swallowing (dysphagia), abdominal distension, musculoskeletal pain, constipation, diarrhoea, flatulence and headache. FOSAMAX is a prescription only medicine, fully subsidised under special authority for those who meet specified criteria. A prescription charge will apply. Consult your doctor to see if FOSAMAX is right for you, a normal doctors visit fee will usually apply. Use only as directed and if symptoms continue or you have side effects, see your doctor, pharmacist or health professional. Marketed by: Merck Sharp & Dohme (NZ) Limited, Newmarket, Auckland. For detailed prescribing information, consult the data sheet or consumer medicine information phone 0800 500 673, or refer to the Medsafe website . [MPI-FSM-2]

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


NZ On Air TV Funding: More Comedy Comes Out Of The Shadows

Paranormal Event Response Unit is a series conceived by Jemaine Clement and Taika Waititi as a TV spin-off from their highly acclaimed feature film What We Do In The Shadows. More>>


Mars News: Winners Announced For The 2016 Apra Silver Scroll Awards

Wellington singer-songwriter and internationally acclaimed musician Thomas Oliver has won the 2016 APRA Silver Scroll Award with his captivating love song ‘If I Move To Mars’. More>>


Scoop Review Of Books: Salt River Songs by Sam Hunt

Colin Hogg, a longtime comrade of Sam, writes in his Introduction that, ‘There is a lot of death in this collection of new poems by my friend Sam Hunt. It’s easier to count the poems here that don’t deal with the great destroyer than it is to point to the ones that do.’ More>>

Electronica: Restoring The World’s First Recorded Computer Music

University of Canterbury Distinguished Professor Jack Copeland and UC alumni and composer Jason Long have restored the earliest known recording of computer-generated music, created more than 65 years ago using programming techniques devised by Alan Turing. More>>


Scoop Review Of Books: Almost Getting Away With Murder

The Black Widow by Lee-Anne Cartier: Lee-Anne Cartier is the sister of the Christchurch man found to have been murdered by his wife, Helen Milner, after an initial assumption by police that his death, in 2009, was suicide. More>>

Howard Davis: Triple Echo - The Malevich/Reinhardt/Hotere Nexus

Howard Davis: The current juxtaposition of works by Ralph Hotere and Ad Reinhardt at Te Papa perfectly exemplifies Jean Michel Massing's preoccupation with the transmigration of imagery in a remarkable triple echo effect... More>>

Get More From Scoop



Search Scoop  
Powered by Vodafone
NZ independent news